Genentech turned 50 this week, and honestly, it’s kind of a big deal for the entire Bay Area. Founded on April 7, 1976, in San Francisco with just 12 employees, this biotech powerhouse basically invented modern genetic engineering and created an entire industry in the process. Governor Gavin Newsom celebrated the milestone by highlighting how the company has fundamentally shaped California’s position as a global innovation leader.

When Genentech started, synthetic human insulin seemed impossible. The company did it anyway, scaling production and proving that “impossible” was just a word. Fast forward five decades, and Genentech has developed over 40 medicines for serious diseases, racked up more than 40 FDA Breakthrough Therapy Designations since 2013, and is now pioneering AI in drug development and patient care. That’s the kind of legacy that doesn’t just happen.

What makes Genentech’s story even more impressive is that it’s stayed rooted in California the entire time. The company’s headquarters remain in South San Francisco, and they’re currently building a $450 million manufacturing facility in Oceanside that’s going to be one of the most advanced biotech production facilities on the planet. They’ve also committed $50 billion to American manufacturing, which is honestly refreshing when you think about where so much production happens these days.

Genentech’s success reflects a larger truth: California is absolutely dominating the innovation economy. Last year alone, California-based tech companies brought in 62 percent of all U.S. venture capital funding. The state is home to 33 of the top 50 privately held AI companies worldwide and leads globally with 25 percent of all AI patents and papers. California’s life sciences sector specifically contributed $396 billion in economic output in 2024 and supports over 1.15 million jobs.

The numbers are kind of wild when you zoom out. One in four U.S. Nobel Prizes in science have gone to California institutions. California life science companies raised over $63 billion in venture capital investment last year alone, more than every other state combined. The state exported $8.3 billion in pharmaceuticals and medicine products and ranked number one in medical equipment and supplies exports.

This isn’t just about money and metrics though. Companies like Genentech have shaped how millions of people live their lives by creating treatments that actually work. As the company looks forward to the next five decades, it’s clear that California’s commitment to pushing boundaries in biotech, AI, and innovation isn’t slowing down anytime soon. The Bay Area’s legacy of turning “impossible” into reality continues.